In this regard, the anti-tumorigenic actions of an anti-CCL2 compound (i.e., Bindarit) were reported in other tumor types, to prevent the infiltration of M2-tumor-associated macrophages and MDSCs into the tumor microenvironment (Zollo et al., 2012). This evidence concerns the gene CCL2 and neoplasm.